Benralizumab
Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD125 |
Clinical data | |
Trade names | Fasenra |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6492H10060N1724O2028S42 |
Molar mass | 146.0 kg/mol g·mol−1 |
![]() ![]() |
Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3][4] It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma.[5] It was also granted orphan drug designation by the FDA for treatment of eosinophilic oesophagitis in August 2019.[6]
References
- Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
- Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs: the investigational drugs journal. 13 (9): 601–604. PMID 20799138.
- AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- Nair, Parameswaran; Wenzel, Sally; Rabe, Klaus F.; Bourdin, Arnaud; Lugogo, Njira L.; Kuna, Piotr; Barker, Peter; Sproule, Stephanie; Ponnarambil, Sandhia; Goldman, Mitchell (2017). "Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma". New England Journal of Medicine. 376 (25): 2448. doi:10.1056/NEJMoa1703501. PMID 28530840.
- "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
- "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Retrieved 2019-10-29.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.